Anti-Mouse CD105 (Endoglin) In Vivo Antibody - Low Endotoxin
Introducing the Anti-Mouse CD105 (Endoglin) In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody specifically targets the CD105 protein, which plays a crucial role in angiogenesis and cardiovascular development, ideal for research in immunology, oncology, and vascular biology. With a rat IgG2a isotype, it ensures high purity and low endotoxin levels (<1.0 EU/mg), making it perfect for use in ELISA, flow cytometry, immunohistochemistry, and other assays.
Available in various sizes, it is formulated in phosphate-buffered saline for stability and efficacy. Enhance your research with this reliable and versatile antibody.
CD105 (Endoglin) is a glycoprotein found on the surface of endothelial cells and is highly expressed in angioactive tissues, including tumors and wound healing sites. It is instrumental in the regulation of transforming growth factor-beta (TGF-β) receptor signaling pathways, contributing significantly to endothelial cell proliferation, differentiation, and migration.
Product Name:
Anti-Mouse CD105 (Endoglin) In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0260
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
MJ7/18
Protein:
CD105
Product Type:
Monoclonal Antibody
Synonyms:
Endoglin, Ancillary TGF-beta Receptor
Isotype:
IgG2a k
Reactivity:
Mouse
Applications:
Agonist, Cell Sep - Pos, ELISA, FC, IF, IF Microscopy, IHC, IHC FF, In Vivo, IP, LCI, WB
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
Agonist, Cell Sep - Pos, ELISA, FC, IF, IF Microscopy, IHC, IHC FF, In Vivo, IP, LCI, WB
Reactivity:
Mouse
Host Species:
Rat
Specificity:
MJ7/18 activity is directed against mouse CD105 (endoglin).
Immunogen:
Inflamed mouse skin
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
CD105 (endoglin) is a TGF-β superfamily co-receptor that promotes angiogenesis, is involved in endothelial integrin-mediated mural cell and leukocyte adhesion, antagonizes TGF-β mediated ERK activation, is essential to the immune response of macrophages, regulates trophoblast differentiation and invasion during pregnancy, promotes T-cell proliferation, and regulates differentiation and collagen expression in myofibroblasts1. CD105 is dysregulated in the vasculature of multiple diseases including cancer, preeclampsia, and hereditary hemorrhagic telangiectasia. Additionally, increased soluble CD105 is associated with numerous cardiovascular pathologies and metabolic disorders with some CD105 polymorphisms being associated with increased risk of cardiovascular damage. CD105 is an effective marker of the tumor vasculature and is a target for early cancer diagnosis and antiangiogenic therapies.
CD105 is alternatively spliced, resulting in both long (L-endoglin) and short (S-endoglin) forms1. The predominant isoform, L-endoglin, promotes the proliferation and migration of endothelial cells via enhanced ALK1-Smad1/5 signaling and is the presumed isoform when not specified in the literature. In contrast, S-endoglin enhances ALK5-Smad2/3 signaling. Endoglin has specific receptor-ligand interactions between type I and type II TGF-β superfamily receptors when binding TGF-β superfamily ligands. Mouse CD105 has three separate regions of similarity to TGF-β receptor III but does not contain the RGD tripeptide found in human CD1052.
MJ7/18 was produced by immunizing rats with inflamed mouse skin and selecting for reactivity with endothelial cells2, 3. MJ7/18 predominantly stains vascular endothelial cells and is a marker of mouse endothelium2, 4.
